A gene-editing tool called Crispr-Cas9 has sparked millions of dollars of investments. Rival research teams that claim patents are going to court to determine who owns the commercial rights.
WSJ.com: Law, Wall Street Journal: Business: Law
Mon, 12/05/2016 - 11:05am
A gene-editing tool called Crispr-Cas9 has sparked millions of dollars of investments. Rival research teams that claim patents are going to court to determine who owns the commercial rights.